HIPRA has launched the first needle-free intradermal vaccine for protection against both Mycoplasma hyopneumoniae (M. hyo) and PCV2, all in one, on the European market.
Due to COVID-19 circumstances and restrictions, the European launch of MHYOSPHERE PCV ID was held online by live streaming with veterinarians from all major European countries attending.
MHYOSPHERE PCV ID is the first vaccine based on an inactivated recombinant Mycoplasma hyopneumoniae strain, called Nexhyon, which represents a new generation of M. hyo vaccines based on recombinant biotechnology. The company said it had developed a ‘new and innovative biological entity’.
The product is ‘ready-to-use’ and arrives with HIPRA’s Hipradermic 3.0, the lightest needle-free intradermal device for swine vaccination with IoT (Internet of Things) connectivity. It will therefore make vaccination against M. hyo and PCV2 quick and easy, the company added.
HIPRA said the new vaccine was part of its ongoing work to provide various types of quality services aimed at improving customers’ businesses.
It has also presented two new associated services. The Together programme analyses the situation of the farm or company with regard to PRRSv, M. hyo and PCV2 associated diseases, and the productive and economic effects of this situation, to support an optimal decision-making.
The other new service, AI Diagnos, consists of an innovative artificial intelligence system (AI) to evaluate lung lesions through images, which can be linked to the economic impact that they have on the farm. As a result the identification of Enzootic Pneumonia is now easier, straightforward, and reliable, the company said.
HIPRA said: “The launch of MHYOSPHERE PCV ID represents a great step forward in the prevention of pig diseases. As one of HIPRA’s commitments says: “Without innovation, there is no project”. HIPRA offers this innovative tool to provide a wide range of benefits to the producer which have been missing up to now.”